Gema

Gema Biotech is a leading Latin American biotechnology company specializing in the development, manufacturing, and commercialization of high-complexity biosimilars and innovative biopharmaceuticals. Based in Argentina and part of the Mega Pharma group, the company focuses on therapeutic areas such as oncology, rheumatology, and endocrinology. Gema Biotech operates state-of-the-art manufacturing facilities that comply with international GMP standards, enabling the production of monoclonal antibodies and recombinant proteins. Their portfolio includes biosimilar versions of blockbuster drugs like rituximab and etanercept, aimed at increasing patient access to life-saving treatments across emerging markets. The company leverages a robust R&D platform to advance its pipeline of complex biologics.